BioPharmSignal logoBioPharmSignal

Biotech News

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

KalVista Pharmaceuticals, Inc. (KALV)KalVista Pharmaceuticals, Inc.Earnings

$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary

Related news

KALVKalVista Pharmaceuticals, Inc.2026-03-18 11:00 EST

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

KALVKalVista Pharmaceuticals, Inc.2026-03-02 12:00 EST

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

View all latest news

KalVista Pharmaceuticals, Inc.

Hereditary Angioedema Company KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks. EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is...

Recent company news

KALVKalVista Pharmaceuticals, Inc.2026-06-11 12:41 EST

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

KALVKalVista Pharmaceuticals, Inc.2026-05-28 11:00 EST

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KALVKalVista Pharmaceuticals, Inc.2026-04-29 11:00 EST

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

KALVKalVista Pharmaceuticals, Inc.2026-04-08 11:00 EST

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KALVKalVista Pharmaceuticals, Inc.2026-04-02 20:01 EST

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
26.95 USD
Market cap
1.43B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States